Clinical Trial Update: Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Folfoxiri plus bevacizumab followed by chemoradiotherapy plus bevacizumab in patients with resectable rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Azienda Ospedaliero, Universitaria Pisana | Conditions: Rectal Cancer | Phase 2 | Status: COMPLETED